Clinical Trial Update: Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 trial assessed the effects of transdermal nicotine on smoking, craving, and withdrawal in people with schizophrenia; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia
• Tobacco Use Disorder

Drugs mentioned

• Nicotine transdermal patch (nicotine patch)

Snippet

Sponsor: National Institute on Drug Abuse (NIDA) | Conditions: Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder | Phase 2 | Status: COMPLETED